Replies to post #13515 on MannKind Corp. (MNKD)

[JLS]

The gist of your story ...

MannKind's Afrezza May Reach Larger Diabetic Population Than Previously Considered
Jul. 28, 2015 12:43 PM ET
Disclosure: I am/we are long "MNKD".

Summary
Needle phobic and needle averse patients are two kinds of diabetics with needle dislike characteristics.
Needle averse patients may have been overlooked in analyst considerations.
Needle averse patients may easily double or triple Afrezza marketshare.

Now, the results of a poll related to needle aversion:

Have you ever delayed part of your diabetes care due to not being up to dealing with needle pain?
Yes ... 11%
No ... 88%
Total votes are 305

http://tinyurl.com/od2qsy3

Note: That 11% (mentioned above) is further diluted by the fact that Type-1 diabetics still need long-term medication.